Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.

Kenneth R Chapman; Jonathan G W Burdon; Eeva Piitulainen; Robert A Sandhaus; Niels Seersholm; James M Stocks; Berend C Stoel; Liping Huang; Zhenling Yao; Jonathan M Edelman; Noel G McElvaney

doi:10.1016/S0140-6736(15)60860-1

Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.

Kenneth R Chapman, Jonathan G W Burdon, Eeva Piitulainen, Robert A Sandhaus, Niels Seersholm, James M Stocks, Berend C Stoel, Liping Huang, Zhenling Yao, Jonathan M Edelman, Noel G McElvaney

Respiratory Medicine, Allergology, and Palliative Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

The efficacy of α1 proteinase inhibitor (A1PI) augmentation treatment for α1 antitrypsin deficiency has not been substantiated by a randomised, placebo-controlled trial. CT-measured lung density is a more sensitive measure of disease progression in α1 antitrypsin deficiency emphysema than spirometry is, so we aimed to assess the efficacy of augmentation treatment with this measure.

Original language	English
Pages (from-to)	360-368
Journal	The Lancet
Volume	386
Issue number	9991
DOIs	https://doi.org/10.1016/S0140-6736(15)60860-1
Publication status	Published - 2015

Subject classification (UKÄ)

Respiratory Medicine and Allergy

Access to Document

10.1016/S0140-6736(15)60860-1

http://www.ncbi.nlm.nih.gov/pubmed/26026936?dopt=Abstract

Cite this

Chapman, K. R., Burdon, J. G. W., Piitulainen, E., Sandhaus, R. A., Seersholm, N., Stocks, J. M., Stoel, B. C., Huang, L., Yao, Z., Edelman, J. M., & McElvaney, N. G. (2015). Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. The Lancet, 386(9991), 360-368. https://doi.org/10.1016/S0140-6736(15)60860-1

@article{db4f97f80b5b4185a1a6245da19bbe27,

title = "Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.",

abstract = "The efficacy of α1 proteinase inhibitor (A1PI) augmentation treatment for α1 antitrypsin deficiency has not been substantiated by a randomised, placebo-controlled trial. CT-measured lung density is a more sensitive measure of disease progression in α1 antitrypsin deficiency emphysema than spirometry is, so we aimed to assess the efficacy of augmentation treatment with this measure.",

author = "Chapman, {Kenneth R} and Burdon, {Jonathan G W} and Eeva Piitulainen and Sandhaus, {Robert A} and Niels Seersholm and Stocks, {James M} and Stoel, {Berend C} and Liping Huang and Zhenling Yao and Edelman, {Jonathan M} and McElvaney, {Noel G}",

year = "2015",

doi = "10.1016/S0140-6736(15)60860-1",

language = "English",

volume = "386",

pages = "360--368",

journal = "The Lancet",

issn = "1474-547X",

publisher = "Elsevier",

number = "9991",

}

Chapman, KR, Burdon, JGW, Piitulainen, E, Sandhaus, RA, Seersholm, N, Stocks, JM, Stoel, BC, Huang, L, Yao, Z, Edelman, JM & McElvaney, NG 2015, 'Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.', The Lancet, vol. 386, no. 9991, pp. 360-368. https://doi.org/10.1016/S0140-6736(15)60860-1

TY - JOUR

T1 - Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.

AU - Chapman, Kenneth R

AU - Burdon, Jonathan G W

AU - Piitulainen, Eeva

AU - Sandhaus, Robert A

AU - Seersholm, Niels

AU - Stocks, James M

AU - Stoel, Berend C

AU - Huang, Liping

AU - Yao, Zhenling

AU - Edelman, Jonathan M

AU - McElvaney, Noel G

PY - 2015

Y1 - 2015

N2 - The efficacy of α1 proteinase inhibitor (A1PI) augmentation treatment for α1 antitrypsin deficiency has not been substantiated by a randomised, placebo-controlled trial. CT-measured lung density is a more sensitive measure of disease progression in α1 antitrypsin deficiency emphysema than spirometry is, so we aimed to assess the efficacy of augmentation treatment with this measure.

AB - The efficacy of α1 proteinase inhibitor (A1PI) augmentation treatment for α1 antitrypsin deficiency has not been substantiated by a randomised, placebo-controlled trial. CT-measured lung density is a more sensitive measure of disease progression in α1 antitrypsin deficiency emphysema than spirometry is, so we aimed to assess the efficacy of augmentation treatment with this measure.

U2 - 10.1016/S0140-6736(15)60860-1

DO - 10.1016/S0140-6736(15)60860-1

M3 - Article

SN - 1474-547X

VL - 386

SP - 360

EP - 368

JO - The Lancet

JF - The Lancet

IS - 9991

ER -

Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.

Abstract

Subject classification (UKÄ)

Access to Document

Fingerprint

Cite this